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Abstract
Background: Cannabis is the most commonly used illicit substance amongst people with psychosis. Continued
cannabis use following the onset of psychosis is associated with poorer functional and clinical outcomes. However,
finding effective ways of intervening has been very challenging. We examined the clinical and cost-effectiveness of
adjunctive contingency management (CM), which involves incentives for abstinence from cannabis use, in people
with a recent diagnosis of psychosis.
Methods: CIRCLE was a pragmatic multi-centre randomised controlled trial. Participants were recruited via Early
Intervention in Psychosis (EIP) services across the Midlands and South East of England. They had had at least one
episode of clinically diagnosed psychosis (affective or non-affective); were aged 18 to 36; reported cannabis use in
at least 12 out of the previous 24 weeks; and were not currently receiving treatment for cannabis misuse, or subject
to a legal requirement for cannabis testing. Participants were randomised via a secure web-based service 1:1 to
either an experimental arm, involving 12 weeks of CM plus a six-session psychoeducation package, or a control arm
receiving the psychoeducation package only. The total potential voucher reward in the CM intervention was £240.
The primary outcome was time to acute psychiatric care, operationalised as admission to an acute mental health
service (including community alternatives to admission). Primary outcome data were collected from patient records
at 18 months post-consent by assessors masked to allocation. The trial was registered with the ISRCTN registry,
number ISRCTN33576045.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: l.sheridanrains@ucl.ac.uk
1Division of Psychiatry, University College London, London, UK
Full list of author information is available at the end of the article
Sheridan Rains et al. BMC Medicine          (2019) 17:161 
https://doi.org/10.1186/s12916-019-1395-5
(Continued from previous page)
Results: Five hundred fifty-one participants were recruited between June 2012 and April 2016. Primary outcome
data were obtained for 272 (98%) in the CM (experimental) group and 259 (95%) in the control group. There was
no statistically significant difference in time to acute psychiatric care (the primary outcome) (HR 1.03, 95% CI 0.76,
1.40) between groups. By 18 months, 90 (33%) of participants in the CM group, and 85 (30%) of the control groups
had been admitted at least once to an acute psychiatric service. Amongst those who had experienced an acute
psychiatric admission, the median time to admission was 196 days (IQR 82, 364) in the CM group and 245 days (IQR
99, 382) in the control group. Cost-effectiveness analyses suggest that there is an 81% likelihood that the
intervention was cost-effective, mainly resulting from higher mean inpatient costs for the control group compared
with the CM group; however, the cost difference between groups was not statistically significant. There were 58
adverse events, 27 in the CM group and 31 in the control group.
Conclusions: Overall, these results suggest that CM is not an effective intervention for improving the time to acute
psychiatric admission or reducing cannabis use in psychosis, at least at the level of voucher reward offered.
Keywords: Financial incentives, Contingency management, Cannabis, Psychosis, Early intervention, Substance misuse
Background
Cannabis is the most commonly used illicit substance
amongst people with psychosis [1]. In longitudinal stud-
ies, cannabis use in first episode psychosis is associated
with substantially higher acute psychiatric admission
rates [2]: an Australian study reported a 51% admission
rate over 15 months follow-up amongst substance users
(mostly cannabis) compared with 17% amongst non-users
[3], accompanied by a threefold difference in inpatient ad-
mission rates. Similarly, a Dutch study reported a 42% ad-
mission rate amongst persistent cannabis users compared
with 17% amongst those who never used or stopped
round the time of first onset [4]. A dose-response relation-
ship between severity of cannabis misuse and time to ad-
mission was also reported in this study. Problematic
cannabis use in psychosis is also associated with marked
delays in remission [5], and lower engagement in work or
education, as well as poorer outcomes in other clinical
and social domains [3, 6, 7]. Despite the clear need for ef-
fective treatments in this group, so far none have been
identified. A Cochrane review [8] of psychosocial inter-
ventions for substance misuse in severe mental illness
identified 32 randomised controlled trials but found little
evidence that any type of therapy was more effective than
treatment as usual, including Cognitive Behavioural Ther-
apy and Motivational Interviewing.
Contingency management (CM) is an operant condi-
tioning-based intervention for substance misuse that
typically uses financial rewards to reinforce target behav-
iours, such as abstinence from substance use or treat-
ment adherence. CM has an increasingly substantial
evidence base in a variety of contexts, including cannabis
misuse [9–11], smoking cessation [12], heavy drinking
[13], and other illicit drug misuse [14, 15]. The National
Institute for Health and Care Excellence (NICE) advo-
cates its adoption in England in the management of sub-
stance use [16]. In a review conducted by NICE as part
of its guidance of psychosocial interventions for sub-
stance misuse, 14 trials of CM were identified, all from
the USA, of which three involved cannabis use. A con-
sistent finding of a benefit for CM was reported, with
most studies using abstinence at 12 weeks as their out-
come measure. In the context of severe mental illness, a
number of trials have found CM to be effective in redu-
cing use in patients with severe mental illness for alcohol
[17], stimulant use [18], and cigarette smoking [19]. This
includes one fairly recent trial of a 12-week CM inter-
vention for stimulant misuse that found the treatment to
be clinical and cost-effective [20].
However, to date there is little research on CM for
cannabis use in severe mental illness, with only one ran-
domised controlled trial [21] reported. The trial found
that CM, combined with an enhanced treatment as usual
psychosocial intervention (Supportive Treatment for Ad-
diction Recovery), resulted in more drug-free urines, re-
duced hospitalisation, and better quality of life than
treatment as usual alone. However, only a small propor-
tion of participants abused cannabis (7%), with 93%
abusing cocaine or heroin. Beyond this, there have also
been three small feasibility studies [22–24], which taken
together also provide some evidence that CM may be
feasible, acceptable, and efficacious in this cohort. Fur-
thermore, with the exception of a small number of re-
cent evaluative studies in Europe [25], the evidence base
for CM is drawn almost entirely from the USA. There is
relatively little experience of using CM in the UK, with
only a few studies reported in any clinical group. Some
recent examples include the CONMAN trial, which pro-
vided an evidence base for CM in uptake of hepatitis B
vaccines amongst opiate users [26], and FIAT, which
found incentives to be effective for reinforcing adher-
ence to antipsychotic medication [27].
The present study investigated the clinical and cost-ef-
fectiveness of CM for reducing cannabis use and thus
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time to acute psychiatric admission amongst Early Inter-
vention in Psychosis (EIP) service users. The objectives
were (1) to conduct a pilot study of a CM intervention
for cannabis use in early psychosis, (2) if the pilot was
successful, to proceed with a full multi-centre pragmatic
randomised controlled trial, (3) to test whether the inter-
vention results in an increase in the time to acute psy-
chiatric admission (the primary outcome), (4) to test
whether the intervention results in a decrease in canna-
bis use, reduced positive psychotic symptoms, and in an
increase in participation in work or education (second-
ary outcomes), (5) to assess the cost-effectiveness of the
intervention from an NHS perspective.
Methods
Trial design and participants
CIRCLE was a rater-blind, multi-centre randomised con-
trolled trial with two arms. The experimental (CM)
group received a 12-week CM intervention together with
a Treatment-As-Usual (TAU) package targeting cannabis
use, which was a standardised and optimised psychoedu-
cational package of the type of psychoeducational inter-
vention recommended in EIP practice [28]. The control
group received the optimised TAU psychoeducational
intervention only. Assessments were performed at the
time of consent, at 3 months (treatment end), and at 18
months following trial inclusion. The primary outcome
was time to acute psychiatric admission, operationalised
as admission to an acute mental health service. Ethical
approval for the trial was received on 16 March 2012
from the London – South East National Research Ethics
Service committee (REC reference 11/LO/1939). The
trial was conducted according to the trial protocol pub-
lished by Johnson et al. [29], and trial procedures are de-
scribed here only in brief. Oversight was provided by an
external Trial Steering Group that was appointed as
agreed by the funding body.
Participants were recruited via EIP services throughout
the Midlands and South East of England. Sites were
added to the trial until the recruitment target was
achieved. EIP services accept individuals who have de-
veloped psychotic illness for the first time and aim to
treat the initial episode early and effectively, minimising
acute psychiatric admissions and optimising clinical and
social recovery. They are now standard provision in Eng-
lish mental health Trusts following policy mandates, and
typically work with service users for 3 years prior to dis-
charge to primary care or to other mental health teams
for continuing care [16]. Inclusion criteria were (1) on
an EIP service caseload, (2) having used cannabis at least
once in 12 out of the previous 24 weeks, (3) age 18–36,
(4) living in stable accommodation, (5) sufficient English
to understand fully and answer the assessment instru-
ments, (6) able to give informed consent to participate,
(7) not subject to a compulsory community treatment or
court order requiring urine testing for cannabis, (8) not
in receipt of treatment for cannabis use from another
agency, and (9) not compulsorily detained in hospital, or
in prison.
Randomisation and masking
Following the baseline assessment interview, participants
were randomised with a 1:1 ratio, stratified on severity
of cannabis use (1–3 uses per week, > 3 uses per week).
An independent randomisation service was used, coordi-
nated by Priment Clinical Trials Unit based at University
College London. Primary outcome assessors were
masked to allocation throughout the trial. Secondary
outcome assessors were masked to allocation at follow-
up assessments in the main trial. However, masking was
not feasible at the 3-month assessment interview in the
pilot as sufficient researchers were not available for dif-
ferent staff to conduct initial and follow-up assessments.
The statistical and health economics analysis plans were
finalised before database lock and statisticians and health
economists undertaking the analysis were masked to
trial arm allocation.
Procedures
The intervention under evaluation was 12 weeks of CM
delivered by clinical staff, who included graduates with-
out mental health professional qualifications, such as as-
sistant psychologists. Participants attended weekly CM
sessions at which they were immediately rewarded with
vouchers if urinalysis indicated cannabis abstinence since
the previous session. Urinalysis was performed using a
small bench-top analyser capable of providing rapid test
results of drug of misuse urinary concentration (Kai-
wood CHR-110). To perform the analysis, the clinician
pipetted a fixed amount of urine into a buffer solution
tube to give a 7:1 serial dilution. This allowed a standard
50 ng/ml marijuana test cassette placed in the analyser
to provide a urine cannabis concentration reading
between 0 and 350 ng/ml. Guidelines were provided to
all staff delivering the intervention to allow interpret-
ation of the test results. The guidelines set out upper
and lower thresholds for urinary tetrahydrocannabinol
(THC) based on recommendations from the suppliers of
the urinalysis equipment, Surescreen Diagnostics. Re-
sults greater than the upper threshold (350 ng/ml)
clearly indicated use within the last week, so were not
rewarded. Results below the lower threshold indicated
urinary THC concentration below 50 ng/ml, the ac-
cepted standard for detecting urinary THC, so were
rewarded. Within these thresholds, urinary THC was ex-
pected to fall each week until it reached the lower THC
threshold, which should be reached within 1 month. A
drop in urinary THC would receive the reward. A
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similar result to, or higher than, the previous week
would fail. A temperature strip on the side of the speci-
men cup allowed staff to check whether the sample had
been tampered with.
The CM schedule and rules were adapted from Bud-
ney et al. [10, 11], which both investigated CM for can-
nabis misuse. It used a variable reward schedule that
began at £5 for providing a baseline sample in the first
week. In the pilot, voucher values rose by £2 each week,
with a £10 bonus voucher every other session. Based on
feedback from clinicians and service users, the schedule
was simplified in the main trial. The voucher value rose
by £5 every two clean samples and the bonuses were re-
moved. In total, participants could receive £240
(US$307, €267 equivalent (11 Jan. 2019)) in vouchers in
both versions of the reward schedule. If a participant
submitted a urine specimen indicating cannabis use in
the previous week, they would receive a £5 voucher. Pa-
tients who failed to attend intervention sessions or sub-
mit a scheduled specimen did not receive a voucher. If
the participant attended the next week and provided a
negative sample, they were rewarded with £10. In the
subsequent week, if the participant provided a second
consecutive negative sample, the voucher values re-
sumed from the highest previous level of reward. Partici-
pants could arrange in advance to miss scheduled
sessions and still receive the reward for that week if they
had a valid commitment that prevented them from at-
tending and they subsequently demonstrated that they
had not used since the previous sessions. They could do
this on a maximum of two occasions for 1 week only
each time. Vouchers were for major supermarkets.
The TAU was a standardised version of a good quality
psychoeducation, which was delivered by EIP staff in a
digital format. It was designed to be sufficiently highly
structured for staff without high-level clinical qualifica-
tions, such as support workers or assistant psychologists,
to be able to deliver it competently following brief train-
ing. The package was comprised of six modules that
were delivered via a standard PC or laptop. Full delivery
of all six modules was intended to take approximately
3 h, normally offered over six regularly programmed ses-
sions of 30 min duration. It included a PDF package for
clinicians to work through with their clients, which
presents information regarding the effects of cannabis,
motivational materials, and strategies for coping, mini-
mising potential harms, and abstaining from cannabis. It
also included video materials, short quizzes, audio files,
and further information and written records of the mod-
ules for the service user to keep. The primary aim was
to deliver information to meet psychoeducation goals
that were tailored to the individual needs of the par-
ticipant, but not to act as a psychological intervention.
It adopted a harm minimisation approach, with an
acknowledgement that in a young person with psych-
osis, cannabis abstinence may be required to ensure
that no harm is done. The content was based on mo-
tivational interviewing principles, relapse prevention,
and harm reduction strategies [link to psychoeduca-
tion package - https://www.ucl.ac.uk/psychiatry/re-
search/epidemiology-and-applied-clinical-research-
depa/projects/circle-trial/trial-materials]. A full day’s
training to provide CM and the TAU psychoeduca-
tional package was delivered to EIP clinical staff by
members of the CIRCLE research team. Training was
tailored to the knowledge and experience of clinicians,
some of whom were assistant psychologists with
psychology degrees, but not mental health professional
training. Clinicians were provided with written docu-
mentation on delivering the CM and the psychoeduca-
tion and supported by the CIRCLE team throughout
the trial. Records of urinalysis results and voucher re-
wards received for each participant were checked by
the CIRCLE research team to ensure fidelity to the
intervention protocol.
Outcomes
The primary outcome was time to admission to an acute
psychiatric service, including psychiatric hospital, crisis
resolution team or crisis house, or other acute mental
health service intended as an equivalent to hospital. The
primary outcome was assessed over an 18-month period
using electronic patient records.
Secondary outcomes were between-group differences
at follow-up for the following: (1) severity of positive
symptoms of psychosis. (2) Social functioning based on
self-reports of engagement in work or study. (3) Self-re-
ported number of days’ cannabis use in the previous 3
months at 3-month follow-up, or the previous 6 months
at 18 months. (4) Proportion of cannabis-free urines at
assessment. (5) Number of admissions over 18 months
follow-up. (6) Quality-adjusted life years (QALYs) (SF-12
and EQ-5D) and service use (CSRI) were used in the
cost-effectiveness analyses. Baseline and secondary out-
come data were collected primarily during assessment
interviews. Some secondary outcome data were checked
or collected using electronic patient records at each as-
sessment. The following measures were performed at all
assessment interviews:
 Demographics, most recent diagnosis, and social
information. Where feasible, data were checked
using patient records.
 Cannabis use
○ The timeline followback (TLFB) [30] was used
to record self-reported substance use, including
cannabis, other illicit substances, and alcohol, over
the previous 6 months at baseline and 18 months,
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and over the previous 3 months at the 3-month
follow-up assessment interview.
○ Structured Clinical Interview for DSM IV
(SCID) part E was used to assess history of alcohol
and substance misuse disorders.
○ Urinalysis for cannabis, performed using a
commercially available immunoassay test for
metabolites of the cannabinoid
tetrahydrocannabinol (THC) using the standard
cut-off of 50 ng/ml [31].
 Psychotic symptoms
○ The positive and negative symptom subscales
of the Positive and Negative Syndrome Scale
(PANSS) [32].
 Service use and health economic analysis:
○ The Client Service Receipt Inventory (CSRI)
[33] was used to record clinical service use,
medication use, receipt of state welfare benefits,
and use of other state-funded services including
the criminal justice system. Data were collected
for the previous 6 months at baseline and
18 months, and for the preceding 3 months at 3-
month assessment. Data were collected at
assessment interview and checked using patient
records. To minimise attrition, at 18 months, data
were collected from patient records for a subset of
the resources deemed most likely to contribute to
higher costs and that feasibly could be collected.
Patient record data were collected for all patients
still in the trial, unless they had withdrawn or
their patient records could not be identified
○ 12-Item Short Form Survey (SF-12) [34] and
the EQ-5D [35] were used to derive quality-
adjusted life years (QALYs).
○ Details of the participant’s referral to the EIP
service, history of admission to acute mental
health services, and time spent on a Community
Treatment Order (CTO) in the last 6 months at
baseline. At 3 months and 18 months, history of
admission to acute mental health services and
time spent on CTO were recorded since study
inclusion. Data were obtained from patient
records
Statistical methods
The sample size for the trial was 544. This was based on
data suggesting a usual acute psychiatric admission rate
of around 50% over the study timeframe in cannabis
users [3, 4]. A 15% decrease in this rate due to the inter-
vention was considered to be clinically beneficial. Using
a power of 90% and a significance level of 5%, a total
sample size of 460 subjects was determined to be re-
quired. This sample size was based on an analysis of
time to acute psychiatric admission and allowed a 37%
decrease in the hazard of admission (hazard ratio of
0.63) in the intervention group to be detected using a
Cox proportional hazards model. The sample size was
inflated by a factor of 1.06, which assumed that each
clinician delivering the intervention would see an aver-
age of four trial participants, and an intraclass correl-
ation coefficient of 0.02 for clinician clustering, which
gave a total sample size of 488. Finally, the sample size
was inflated by 10% to account for attrition for the pri-
mary outcome, giving a total sample size of 544. This
calculation was performed using Stata version 11 [36].
All analyses were carried out comparing the CM and
control groups as randomised using all available data.
The continuous variables were summarised using mean
(standard deviation (SD)) or median (interquartile range
(IQR)) as appropriate. Categorical variables were pre-
sented as frequencies and percentages. Logistic regres-
sion was used to determine baseline predictors of
missingness. Kaplan-Meier survival curves by rando-
mised groups were used to examine the primary out-
come (time to acute psychiatric admission) descriptively.
A Cox proportional hazards model was used to compare
the primary outcome in the intervention and control
groups, adjusting for severity of cannabis use (the strati-
fication variable; 1 to 3 times a week versus 4 or more
times a week) at baseline and whether the participant
was part of the pilot trial. The assumption of propor-
tional hazards was checked using Schoenfeld residuals
[37]. The supportive analyses for the primary outcome
were as follows:
 Adjusting for significant baseline predictors of
missingness.
 Excluding those participants who had no secondary
outcome data (for 12 weeks and 18 months
separately).
 Including those in the main trial only as some minor
changes were made to the protocol at the end of the
pilot before the main trial commenced
 Adjusting additionally for the number of
psychoeducation sessions attended (which was
offered in both arms of the trial).
 Adjusting additionally for the number of admissions
in the 6 months prior to baseline.
 Adjusting for the same factors as the primary
analysis but using centre as the clustering variable
instead of clinician.
Secondary outcomes were analysed separately at 3 and
18months. Models were adjusted for severity of canna-
bis use at baseline and whether the participant was part
of the pilot trial. For the dichotomous outcomes (canna-
bis-positive urine, engaged in work or study), logistic re-
gression was used. The residuals for the positive and
Sheridan Rains et al. BMC Medicine          (2019) 17:161 Page 5 of 17
negative symptoms from PANSS outcomes were not
normally distributed and were therefore log trans-
formed and analysed using linear regression models.
Zero-inflated Poisson regression was used for count
outcomes including number of cannabis days and
number of admissions over follow-up, as there were
excess zeros in these outcomes. The number of can-
nabis days at 3 months was analysed using Poisson re-
gression. All secondary outcomes were also analysed
after adjusting for predictors of missingness. An add-
itional supportive analysis for number of admissions
was to include all those who were discharged from
psychiatric services within 18 months and assuming
they did not have any admissions over 18 months. Ro-
bust standard errors were used in all regression
models to account for clustering by a clinician deliv-
ering the CM in the analyses [38]. Results from all
supportive and secondary analyses are presented as
estimates and 95% confidence intervals (CI) as speci-
fied in the statistical analysis plan. All analyses were
carried out using Stata version 14 [39].
Health economic analyses
The cost-effectiveness analysis was conducted from an
NHS/social care perspective over 18 months. Costs of
the CM intervention and psychoeducation were calcu-
lated using the salaries of staff delivering the CM and
psychoeducation, supervision time, and overheads.
Other service use was measured with the CSRI and
from data collected from patient records. Costs were
calculated by combining resource use with 2015/2016
unit costs. Average costs were used to cover the gap
between 3 and 12 months. This did not apply to in-
patient costs which were available throughout the fol-
low-up period. Imputation for missing non-inpatient
costs was carried out with predictors being commu-
nity costs for available periods and inpatient costs.
(This was done so that analyses could be conducted
on the sample with complete inpatient data.) Costs
were compared between arms at 18-month follow-up
using a regression model, controlling for baseline, and
with bootstrapped confidence intervals based on the
percentile method and 10,000 resamples.
Quality-adjusted life years (QALYs) were derived
from the EQ-5D-3L and SF-12 (for secondary analyses)
using area under the curve methods incorporating
scores at baseline and 3- and 18-month follow-ups.
Missing utility scores were imputed from all available
scores. QALY comparisons were made after adjusting
for baseline scores. Costs and QALY differences were
obtained from 10,000 bootstrapped resamples. Cost-ef-
fectiveness planes and cost-effectiveness acceptability
curves (CEACs) were generated.
Results
Recruitment and follow-up
Recruitment to the pilot phase occurred between June
2012 and March 2013. The pilot study successfully
achieved its aims by recruiting within 10% of its tar-
get (n = 68), demonstrating the feasibility of recruiting,
delivering the interventions, and retaining at least
60% of participants at 3 months. Subsequently, a full
RCT was performed. Recruitment to the main trial
occurred between October 2013 and March 2016. Fol-
low-up data collection was completed by October
2017. Figure 1 shows the flow of service users
through the trial. Seventy EIP teams took part in the
trial from 23 NHS trusts. Two thousand four hundred
two service users were initially approached by EIP cli-
nicians. Of these, 551 service users gave consent and
were randomised into the trial. Primary outcome data
were obtained for 530 participants (92%). Assessment
interviews were performed with 371 participants at 3-
month follow-up (67%) and 278 participants at 18
months (50%).
Baseline characteristics
Most baseline characteristics were similar between the
two groups. In both groups, over 85% of participants
were male, with a mean age of around 25 (SD 4). 72%
were using cannabis more than three times a week and
reported using on 111 days on average in the previous 6
months. Around a third of participants were diagnosed
with schizophrenia or schizo-affective disorder and half
had diagnoses of other types of psychosis, perhaps in
part because EIP services tend to be reticent about mak-
ing a diagnosis of such as schizophrenia because of con-
cerns regarding stigma and diagnostic instability. A
quarter of participants were currently engaged in some
form of work or education, but a large majority (over
80%) had held open market employment at some point.
Median PANSS positive symptom score was 12 (IQR 9,
17) in the control group and 13 (IQR 9, 16) in the CM
group. Lifetime rates of cannabis dependence were very
high (87% of control and 85% of intervention group
members), and around three quarters in both groups
were dependent at baseline. Lifetime rates of alcohol
misuse or dependence, and of reports of using sub-
stances other than cannabis, were also fairly high (e.g.
47% of control and 52% of intervention group members
reported using cocaine; 36% of control and 32% of inter-
vention group members met the criteria for alcohol de-
pendence) (Table 1). In the 6 months prior to baseline,
median days of substance use other than cannabis were
low (0) in the CM group (IQR 0, 4) and in the control
group (0; IQR 0, 1). Median alcohol using days was 6 in
both the CM (IQR 0, 26) and control groups (IQR 0, 26).
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Participation in CM and psychoeducation
Participants in the CM group obtained a mean of £64
(out of a maximum of £240) in voucher rewards and
attended a median number of 9 (IQR 3, 12) (maximum
of 12) CM sessions. Forty-six participants declined the
CM intervention or did not attend any sessions. Partici-
pants attended a median of 6 and 4 (maximum of 6)
psychoeducation sessions in the CM and control groups
respectively. However, 86 participants in the control
group and 63 in the CM group declined the psychoedu-
cation or did not attend any sessions.
Primary outcome
For the primary outcome, there was no statistically sig-
nificant difference in time to admission to an acute men-
tal health service between the randomised groups
(hazard ratio (HR) 1.03, 95% CI 0.76, 1.40) (Fig. 2 and
Tables 2, 3, and 4).
Supportive analyses
Results from the supportive analyses were similar. The
odds of at least one admission over 18 months of follow-
up were similar across randomised groups (OR 1.02,
Fig. 1 Consort diagram
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95% CI 0.70, 1.48). Approximately, a third of participants
experienced at least one acute admission to a mental
health service, including hospital alternatives such as cri-
sis teams and crisis houses, by 18 months in both the
CM (90/272) and control groups (85/259). Amongst
those who experienced an acute psychiatric admission,
the median number of days until admission was 245
(IQR 99, 382) in the control group and 196 (IQR 82,
364) in the CM group.
Secondary outcomes
For participants who had a full 18 months’ follow-up,
those in the CM group had a slightly higher rate ratio
for number of admissions than those in the control
group (incidence rate ratio (IRR) 1.08, 95% CI 0.75,
1.54); this changed little when assuming those who were
discharged from services had no admissions during fol-
low-up or when including predictors of missingness.
Those in the CM group had lower odds of paid work or
Table 1 Baseline demographics
Characteristic Control Contingency Management (CM)
n/N or median or utility score %, SD, or IQR n/N or median or utility score %, SD, or IQR
Male 240/273 88 238/278 86
Age mean (SD) 25 (4) 24 (4)
Ethnicity
White 144/273 53 148/277 53
Black 62/273 23 65/277 23
Asian 30/273 11 29/277 10
Other 37/273 14 35/277 13
Marital status
Single 253/273 93 259/278 93
Married or cohabiting 14/273 5 17/278 6
Other 6/273 2 2/278 1
Educational attainment
No qualifications 48/273 18 43/277 16
GCSE or equivalent 104/273 38 133/277 48
A level or equivalent 67/273 25 58/277 21
Post 18 education (including HND, trade, degree) 54/273 20 43/277 16
Ever had open market employment 223/273 82 240/278 86
Any current work or study 67/273 25 73/278 26
Diagnosis
Schizophrenia or schizo-affective disorder 80/256 31 90/268 34
Bipolar affective disorder 26/256 10 19/268 7
Depression with psychotic symptoms 11/256 4 5/268 2
Other psychosis 139/256 54 154/268 57
Cannabis use
1–3 times a week 77/273 28 78/278 28
More than 3 times a week 196/273 72 200/278 72
Any work or study 58/183 32 58/189 31
Cannabis-positive urine 210/262 80 214/272 79
Number of days using cannabis* 108 (67, 156) 114 (70, 162)
History of cannabis dependence 238/273 87 236/278 85
Current cannabis dependence 183/238 77 185/236 78
PANSS positive symptoms median (IQR) 12 (9, 17) 13 (9, 16)
PANSS negative symptoms median (IQR) 14 (11, 19) 14 (10, 19)
EQ-5D-3L utility score 0.7619 0.7652
SF-6D utility score 0.6789 0.6833
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study at both 3 and 18 months (OR 0.95, 95% CI 0.62,
1.46; OR 0.82, 95% CI 0.50, 1.35 respectively). However,
those in the CM group also had slightly lower odds of
cannabis-positive urine at 3 and 18 months (OR 0.86,
95% CI 0.56, 1.34; OR 0.84, 95% CI 0.49, 1.41 respect-
ively). None of these results approached statistical sig-
nificance at the 5% level. Illicit substance use other than
cannabis was very low at both follow-ups (3-month me-
dian days of use: 0; IQR 0, 1 in both groups; 18-month:
0 in both groups, IQR 0, 2 in control; IQR 0, 1 in CM).
The median number of alcohol-using days was 4 (con-
trol IQR 0, 12; CM IQR 0, 15) in both groups at
3 months and 6 (IQR 0, 24) in both groups in 18 months.
For the log-transformed PANSS positive outcome at
3 months, the CM group score was on average 7% lower
(better) than the control group (95% CI − 14%, − 0%).
There were 58 reported serious adverse events (SAE). In
the CM group, these were 24 psychiatric hospital admis-
sions and 3 deaths. In the control group, there were 28
psychiatric hospital episodes, 2 deaths, and 1 arrest.1
CM in the context of psychoeducation
A post hoc analysis was performed to help understand
the results in the context of whether people had received
psychoeducation as planned. Attending at least four of
the six psychoeducation sessions planned was selected
as the measure of compliance (137/263 (52%) in the
control group and 168/273 (62%) in the CM group).
There were no marked differences in demographic,
social, or clinical baseline characteristics between com-
pliers and non-compliers between randomised groups. A
dichotomous variable indicating compliance was created.
A Cox model with robust standard errors was con-
ducted. The primary outcome of the trial (time to acute
psychiatric admission) was used as the dependent vari-
able in the analysis. Randomisation group, compliance,
severity of cannabis use at baseline, and whether the par-
ticipant was part of the pilot trial were included as co-
variates, and an interaction term between compliance
and randomisation groups was used. The interaction
term was statistically significant (p value for interaction
0.016), which suggests that CM might be effective in
participants who receive sufficient psychoeducation. This
may be due to the psychoeducation being effective
amongst those who engaged with treatment, and engage-
ment was higher in the CM group.
Health economics
Intervention costs were on average £298 for the CM
group and £140 for controls. Inpatient use (based on
531 participants) over the follow-up period was virtually
the same between trial arms, with around one quarter
receiving this and for about 3 months across the period
(Table 4). Other service use (based on the smaller sam-
ple of 231 who were followed up with the CSRI) was
relatively similar between the arms over the follow-up
period. Costs for drug and alcohol services were how-
ever greater for the CM group. After imputation, the
mean (SD) health and social care costs over the 18-
month period were £15,614 (£29,360) for the CM group
and £16,620 (£33,283) for controls. After adjusting for
baseline costs, the CM group had costs that were on
average £1625 lower than for controls (bootstrapped
95% CI, − £3355 to £6869).
EQ-5D-3L and SF-6D utility scores increased gradually
over time for both groups (Table 2). The total mean
QALYs over the follow-up based on the EQ-5D-5L were
1.2218 for the CM group and 1.1855 for controls.
Adjusting for baseline utility, CM resulted in 0.034 more
QALYs than controls. QALYs based on the SF-6D scores
were 1.0682 for CM and 1.0585 for controls. With ad-
justment, CM resulted in 0.0063 more QALYs than con-
trols. Therefore, CM had lower costs and produced
more QALYs and so ‘dominated’ the control. There is
uncertainty around the results shown by the cost-effect-
iveness planes. With the EQ-5D-3L (Fig. 3), the most
likely result is that CM has lower costs and better out-
comes (72% of replications), followed by higher costs
and better outcomes (26%), lower costs and worse out-
comes (2%), and higher costs and worse outcomes (1%).
With the SF-6D, there is more uncertainty (Fig. 4), but
the most likely outcome is still CM having lower costs
and better outcomes (52%), followed by lower costs and
Fig. 2 Kaplan-Meier survival curve by randomised group for the
primary outcome, time to an acute psychiatric admission
1While all SAEs were recorded during the intervention period, as the
research team did not have regular, direct contact with participants
during the post-treatment follow-up phase, detection of SAEs was
heavily dependent on EIP clinicians reporting them to the research
team. While all deaths were reported by the EIP teams and recorded
as SAEs, primary data collection shows that not all arrests or inpatient
episodes were reported to the research team once the intervention had
ended
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worse outcomes (22%), higher costs and better outcomes
(18%), and higher costs and worse outcomes (8%). The
CEACs (Fig. 5) show that even with a zero value at-
tached to a QALY there is still a high probability of CM
being the most cost-effective option. At a threshold
value of £20,000, the probabilities are 0.81 for the EQ-
5D-3L and 0.75 for the SF-6D.
Discussion
The results of this trial indicate that CM confers no
clinical advantage over TAU for patients with psych-
osis who use cannabis. Neither was any effect seen in
our secondary outcomes, including cannabis use, en-
gagement in work or education, and positive psych-
otic symptoms. However, a post hoc analysis found
that compliance with psychoeducation in the CM arm
resulted in a statistically significant improvement in
time to acute psychiatric admission, while the same
was not true for the control group. This suggests that
CM had a clinical benefit amongst those who also en-
gaged with psychoeducation.
The economic analyses show that the costs associated
with CM were less than for the TAU, although the differ-
ence was not statistically significant and this analysis
Table 2 Outcomes at 3 months (treatment end) and 18 months
Control CM
n/N, mean, or
median
% or
(IQR)
n/N, mean, or
median
% or
(IQR)
Admitted to an acute mental health service 18
months
85/259 33 90/272 33
Number of admissions 18
months
0 (0, 1) 0 (0, 1)
Any work or study 3 months 58/183 32 58/189 31
18
months
45/135 33 42/145 29
Cannabis-positive urine 3 months 122/170 72 128/184 70
18
months
76/124 61 77/136 57
Number of days using cannabis* (median) 3 months 30 (3, 84) 26 (1, 67)
18
months
26 (1, 142) 26 (0, 118)
PANSS positive symptoms (median) 3 months 11 (8, 16) 10 (8, 14)
18
months
10 (8, 15) 11 (8, 13)
PANSS negative symptoms (median) 3 months 14 (10, 18) 12 (9, 17)
18
months
12 (8, 17) 12 (9, 17)
Number of days of using illicit substances other than cannabis
(median)
3 months 0 (0, 1) 0 (0, 1)
18
months
0 (0, 2) 0 (0, 1)
Number of days using alcohol (median) 3 months 4 (0, 12) 4 (0, 15)
18
months
6 (0, 24) 6 (0, 24)
EQ-5D-3L utility score (mean) 3 months 0.7729 0.8175
18
months
0.8032 0.8336
SF-6D utility score (mean) 3 months 0.7018 0.7114
18
months
0.7110 0.7205
Number of psychoeducation sessions attended (median) 4 (0, 6) 6 (1, 6)
Number of contingency management sessions attended (median) 9 (3, 12)
Number who attended 4 or more PE sessions (used in the post hoc
analysis)
137/263 52 168/273 62
*At 3 months, this was for the previous 12 weeks/84 days. At 18 months, this was for the previous 168 days
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Table 3 Analysis of primary and secondary outcomes in terms of contingency management
Outcome Estimate* 95% CI N Estimate† 95% CI N
Time to acute psychiatric admission (HR) 1.03 (0.76, 1.40) 531 1.02 (0.75, 1.40) 531
Cannabis-positive urine sample 3 months (OR) 0.86 (0.56, 1.34) 354 0.85 (0.55, 1.32) 352
Cannabis-positive urine sample 18 months (OR) 0.84 (0.49, 1.41) 260 0.85 (0.50, 1.43) 260
log PANSS positive symptoms 3months − 0.07 (− 0.14, −
0.00)
366 − 0.07 (− 0.14, −
0.00)
364
log PANSS positive symptoms 18 months −0.04 (− 0.13, 0.05) 276 − 0.04 (− 0.13, 0.04) 276
log PANSS negative symptoms 3months − 0.08 (− 0.16, 0.00) 362 − 0.08 (− 0.16, 0.00) 360
log PANSS negative symptoms 18 months 0.01 (− 0.08, 0.11) 276 0.02 (− 0.08, 0.11) 276
Paid work or study at 3 months (OR) 0.95 (0.62, 1.46) 372 0.94 (0.60, 1.47) 370
Paid work or study at 18 months (OR) 0.82 (0.50, 1.35) 280 0.82 (0.50, 1.35) 280
Number of days cannabis used in the previous 12 weeks (3 months follow-up) (IRR) 0.89 (0.75, 1.04) 371 0.88 (0.75, 1.04) 369
Number of days cannabis used in the previous 6 months (18 months follow-up)
(IRR)
1.09 (0.88, 1.36) 274 1.08 (0.87, 1.33) 274
Number of admissions over 18 months follow-up 1.08 (0.75, 1.54) 374 1.09 (0.76, 1.55) 374
At least one admission over 18months follow-up (OR) 1.02 (0.70, 1.48) 531 1.01 (0.69, 1.48) 531
CI confidence interval, HR hazard ratio, OR odds ratio, IRR incident rate ratio
* Adjusting for level of cannabis use at baseline and whether in the pilot study
† Additionally adjusting for baseline predictors of missingness. These are:
Time to admission, number of admissions, at least one admission: any work or study
Urine positive 3months, PANSS positive 3 months, PANSS negative 3 months, any work or study 3months, number of days cannabis use 3 months: exempt from
work due to disability
Urine positive 18months: any work or study
PANSS positive 18 months, PANSS negative 18months, any work or study 18months, number of days cannabis use 18 months: voluntary work
Table 4 Service use for the health economics
Service Control CM
% users Mean (SD contacts) Mean (SD) cost % users Mean (SD) contacts Mean (SD) Cost
Inpatient stays 25.5 90.9 11,931 24.6 89.4 11,339
Early intervention team 68.9 11.1 303 68.7 11.7 302
GP 44.7 2.9 134 51.1 3.1 127
Psychiatrist 53.1 3.2 479 54.3 3.2 404
Psychologist 20.9 5.6 445 22.7 5.0 416
Home treatment/crisis team 10.3 12.8 21 9.0 10.7 302
Mental health nurse 13.9 7.0 129 15.1 9.1 127
Adult education class 3.7 9.0 18 2.5 5.4 404
Assertive outreach team 1.1 9.0 5 1.8 8.4 4
Class/group at a leisure centre 4.4 25.2 33 4.0 14.6 10
Community mental health centre 2.6 7.6 40 4.3 8.8 79
Day care centre/day hospital 0.7 27.0 3 1.4 5.2 4
Drop-in centre 4.8 10.8 33 1.4 16.5 12
Drug/alcohol service 4.8 6 23 4.0 16.0 163
Drug and alcohol advisor 10.6 7.9 116 9.4 5.5 291
Occupational therapist 7.0 3.7 62 6.1 2.1 37
Other counsellor/therapist 5.1 7.6 156 4.0 7.6 53
Other doctor 8.1 3.7 75 7.6 2.1 26
Self-help/support group 5.1 6.5 9 7.2 6.8 16
Social worker 10.3 7.5 58 7.9 10.4 44
Medication 288 308
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was carried out after imputation for a large proportion
of cases, while we had primary outcome data for most
who entered the trial. QALY differences based on the
EQ-5D-3L were relatively large compared to other stud-
ies, but less so with the SF-6D. The lower costs and
greater number of QALYs mean that CM is more cost-
effective than TAU even though the differences for both
costs and QALYs were not statistically significant. While
interpretation of this is complex as there was little differ-
ence between CM groups in the intention-to-treat
analyses, one possible explanation is that time to acute
psychiatric admission was better amongst those who
complied with psychoeducation in the CM group, but
not the control group. The admission rate was lower
than anticipated in the trial as a whole. Only around a
third in each group required admission to acute care,
while it was expected [3, 4] for the purposes of our sam-
ple size calculation and based on previous literature that
half would experience an acute psychiatric admission.
This suggests that a comparatively stable group of
Fig. 3 Cost-effectiveness plane based on EQ-5D-3L
Fig. 4 Cost-effectiveness plane based on SF-6D
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patients was recruited to trial and/or that the psychoe-
ducation and/or the extra attention of being in a re-
search study had a beneficial impact. Although the
majority still had cannabis-positive urine, the number of
reported cannabis-using days in the previous 6 months
fell from over 100 to 26 in each group by 18-month fol-
low-up, indicating that cannabis use declined in both
groups over this period. This could be due to the psy-
choeducation intervention, the normal progression of
use in this group, regression to the mean, or a combin-
ation of these factors. Low levels of self-reported illicit
substance and alcohol use at follow-up indicate that
people were not substituting them for cannabis.
Overall, the results of the trial are mixed, and stand in
contrast to the frequently positive benefits reported for
CM interventions [15, 16], including for substance mis-
use in psychosis [17–19, 21]. Reasons for this are un-
clear; however, some possible explanations include the
following: Firstly, offering more frequent CM sessions or
offering a higher reward might have been more clinically
effective. The CM schedule was adapted from two trials
by Budney et al. [10, 11], which both found a positive ef-
fect in cannabis misuse. However, the reward sessions in
one of those trials occurred once per week, while in the
other they occurred twice per week. Bellack et al. [21],
which is the only other trial of CM to include cannabis
in severe mental illness, also used a twice weekly reward
schedule. CIRCLE was intended to be a pragmatic trial
of a CM intervention in an EIP context, and based on
feedback from EIP clinicians, it was thought that deliver-
ing sessions more frequently than once per week would
not be feasible, while the reward value was intended to
be substantial enough to incentivise abstinence without
being viewed as too lavish and thus ethically problem-
atic, and was supported by clinicians, service users
involved in the patient and public involvement consult-
ation, and experts in the field. It was also approximately
in line with other trials in this field (e.g. [10, 21]). How-
ever, it was lower than that offered in some feasibility
studies that found a positive effect (e.g. [22, 23]). Further
discussions with stakeholders and experts in the field
might elucidate this issue.
Secondly, cannabis dependence was high in this sam-
ple (around three quarters of participants at baseline),
and those with dependence may find it harder to change
their behaviour compared to those with less-severe
problematic cannabis use. However, in the two trials by
Budney et al. [10, 11] and Bellack et al. [21], all partici-
pants were dependent, and so it is unlikely that the CM
intervention failed to provide a benefit because of high
rates of dependence. An alternative explanation is that
participants may have been using more highly potent
forms of the cannabis and consequently may have found
it more difficult to abstain than those using less-potent
forms. There is good evidence that this cohort typically
uses more potent forms of cannabis than non-psychiatric
groups [40] and that high potency cannabis use is rela-
tively prevalent in London, where much of our sample
was recruited [41]. It is therefore plausible that use of
highly potent types of cannabis may have been relatively
widespread in our sample. However, we did not system-
atically record the type of cannabis participants were
using, making further exploration of this possibility
difficult.
Fig. 5 Cost-effectiveness acceptability curves
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Thirdly, while engagement was good with people at-
tending a median of 4 psychoeducation sessions in the
control group and 6 in the CM group, a substantial pro-
portion of people (around one third of people in the
control group and one fifth in the CM group) declined
to take part in either the CM and/or the PE or did not at-
tend any sessions. This suggests there may have been a
substantial minority who were not particularly motivated
to quit cannabis, but perhaps participated due to the en-
thusiastic approach to recruitment by staff and researchers
and/or the small payment received to acknowledge base-
line interview assessment participation. Recruitment was
slower than anticipated, partly because fewer service users
than expected wanted to enter treatment for cannabis use.
The post hoc analysis results suggested that people who
were motivated to adhere to the psychoeducation had bet-
ter outcomes. It may be that a more engaged cohort
would have benefited more from the CM.
Fourthly, patients in this cohort are often multiply dis-
advantaged [2, 5, 42], which is likely to make behavioural
change much more challenging. This includes being less
likely to be in work or education, having poorer social
networks, and thereby being more socially isolated but
also the nature of psychotic illness itself, which can in-
clude greater disorganisation, poorer social skills, and
lower motivation [43, 44]. It may be that interventions
are needed in this cohort that have a broader focus than
just reducing cannabis use. It may be that a better ap-
proach would support patients in becoming less socially
isolated or spending less time with cannabis-using peers,
as well as helping them back into work or engaging in
other meaningful activities.
Finally, the trial focused only on cannabis, but baseline
data indicated considerable history of alcohol and sub-
stance use disorders. It may be that the CM would have
been more effective if it had addressed these additional
substances as well.
There were several limitations to the study. Firstly,
CIRCLE was a pragmatic trial of a CM intervention de-
livered in EIP services in the UK. The CM and psychoe-
ducation treatments were designed to be feasible for EIP
clinicians to deliver in routine practice, which required
limiting the additional workload to clinicians. As such,
during the intervention period, urinalysis samples were
only collected from the CM group and not controls.
This makes it more challenging to analyse whether the
CM group participants reduced their use more than the
controls during the intervention period. However, self-
reported days of cannabis use at treatment end did not
differ between groups, suggesting no impact from the
CM. However, CIRCLE should be viewed as a trial of a
pragmatic CM intervention rather as a definitive trial of
whether CM reduces cannabis use in psychosis. Studies
that more rigorously assess drug use in both treatment
groups are needed to investigate whether CM could be
effective at reducing use in psychosis.
Secondly, the inclusion of an active control makes it
more difficult to interpret results. The fall in cannabis
use across the trial population suggests there may have
been benefit from the enhanced TAU. While it was
intended to be a standardised form of treatment as usual,
it became apparent that it was a much better developed
and more ambitious psychoeducation than was otherwise
available in many of the participating EIP teams.
Thirdly, originally, the CM (and psychoeducation) was
originally intended to be delivered by care coordinators
(the nurses, occupational therapist or social workers
with primary responsibility for keeping in touch with pa-
tients and organising their care). However, few care co-
ordinators were prepared to deliver the interventions,
largely due to concerns regarding time pressures and po-
tential disruption to therapeutic relationships. Instead,
other clinical staff, such as support workers or assistant
psychologists, were trained to deliver it. Greater integra-
tion into routine care may have improved its effective-
ness. However, data on delivery of the CM intervention
suggested that those delivering it did adhere well to the
intended protocols, and it may be that care coordinators
would have been less successful in this.
Fourthly, while the follow-up rate for the primary out-
come was very high, attrition was greater than antici-
pated on the interview measures, potentially introducing
response bias.
Fifthly, while a standard threshold was used for the
urinalysis at assessment interview (50 ng/ml), a lower
threshold would have given a slightly more accurate
measure of abstinence rates. A lower threshold may have
identified a small difference between groups. However,
as there was no difference in either the proportion of
cannabis-free urine using a threshold of 50 ng/ml or
self-reported days of use at either follow-up, it seems
unlikely that a clinically significant difference would be
identified.
Sixthly, while we approached all EIP patients who were
identified to trial researchers as potentially eligible by
their clinicians and who agreed to be contacted by a trial
researcher, it may be that gate-keeping by EIP clinicians
or self-selection by patients could have introduced bias.
However, this was a pragmatic RCT and it is likely that
the trial sample is a good reflection of the range of char-
acteristics of the EIP service users who would enter
treatment if the intervention was offered through EIP or
specialist drug treatment services. Similar issues seem
likely if the intervention was introduced as part of rou-
tine care.
Seventhly, we did not systematically record the type of
cannabis participants were using. It may be that those using
more potent types of cannabis would respond differently to
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the intervention compared to those using milder forms, ei-
ther by finding it harder to change behaviour, or potentially
by showing greater benefit from the CM treatment in terms
of acute psychiatric service use.
Eighthly, although not a limitation in the analyses, the
finding that CM has over 80% likelihood of being cost-
effective needs to be treated with caution. In the sample
that were followed up at both time points, the costs
were lower and QALY outcomes better for the CM
group compared to controls, and this led to a favourable
cost-effectiveness ratio for CM which applied to most
bootstrapped resamples. The cost and QALY differences
were though limited and not statistically significant.
Finally, using acute psychiatric admission as the out-
come is a pragmatic choice because it is routinely avail-
able data that are relatively accessible via patient
records. But it is limited in that some acute psychiatric
episodes are likely to be contained without acute service
use, for example, it may be handled by the EIP team in-
stead, and also that thresholds for admission to acute
care may vary considerably, for example by clinician and
by area.
Conclusions
Overall, the lack of effectiveness of CM in these
intention-to-treat analyses means that it cannot be rec-
ommended as an intervention to reduce cannabis use in
patients with recent onset psychosis. However, the ad-
herence and health economic analyses suggest that ef-
fectiveness of CM might be better amongst those who
engage well with psychoeducation, or if a different re-
ward value or schedule was offered. Further investigation
of stakeholder perspectives would be useful to explore
the latter possibility. However, overall, this is another
trial that demonstrates how challenging it is to address
the problem of cannabis use in psychosis. It may be that
a substantially different approach is required to address
this significant clinical problem. It has been noted that
young people who have psychosis and problematic can-
nabis use are often multiply disadvantaged. Despite this,
trials of interventions in this area are often narrowly fo-
cused on changing cannabis use. A more inclusive man-
agement that takes in patients’ social contexts, including
engagement in work or education, might prove more
fruitful.
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